India, Aug. 7 -- The Government of India has issued a release:
Name of State
No. of projects approved
Investment(in crore Rs.)
Capacity (in MT)
Production Qty.(in MT)
Production value(in crore Rs.)
Incentive released (in crore Rs.)
Committed
Actual
Committed
Installed
2023- 24
2024- 25
2025- 26
2023-24
2024- 25
2025- 26
Andhra Pradesh
10
1,745.7
2,676
24,390
16,468
224.4
1,207.4
5,498.6
63.2
258.4
865.7
31.91
Gujarat
8
330.9
407.3
14,270
13,959
7,028.7
4,170
5,572.7
209.5
133.1
162.9
11.3
Haryana*
1
81
37
800
NIL
NIL
NIL
NIL
NIL
NIL
NIL
NIL
Himachal Pradesh
2
806.8
502.6
1,100
400
0.01
69.9
172.1
0
115.9
242.6
11.98
Jammu & Kashmir*
1
185
338.65
1,000
NIL
NIL
NIL
NIL
NIL
NIL
NIL
NIL
Karnataka
3
96.9
201.4
37
16.7
0
0
0.9
0
0
3.12
NIL
Madhya Pradesh
2
280
101.8
1,015
15
3.63
4.93
0.32
24.71
33.37
3.2
NIL
Maharashtra
5
308.4
168.8
40,185
19,180
611.9
500.3
1.14
27.51
26.41
0.01
NIL
Punjab
1
137.7
161.1
180
206
91.4
79.6
58.15
119.53
96.9
72.01
27.18
Tamil Nadu
2
31.5
45.6
280
280
3.1
0.0025
5.73
0.8
0.01
1.24
NIL
Telangana
13
326.02
430.2
7,820
7,820
103.1
89.4
108.03
87.4
85.8
101.5
5.23
S. No.
Name of KSM/DI/API
Key Fermentation based KSMs / Drug Intermediates
1
Penicillin G
2
7-ACA
3
Erythromycin Thiocynate
(TIOC)
4
Clavulanic Acid
Fermentation based niche KSMs I Drug Intermediates I APIs
5
Neomycin
6
Gentamycin
7
Betamethasone
8
Dexamethasone
9
Prednisolone
10
Rifampicin
11
Vitamin BI
12
Clindamycin Base
13
Streptomycin
14
Tetracycline
Key Chemical Synthesis based KSMs I Drug Intermediates
15
1,1 Cyclohexane Diacetic
Acid (CDA)
16
2-Methyl-5Nitro-lmidazole
(2-MNI)
17
Dicyandiamide (DCDA)
18
Para amino phenol
Other Chemical Synthesis based KSMs I Drug Intermediates / APIs
19
Meropenem
20
Atorvastatin
21
Olmesartan
22
Valsartan
23
Losartan
24
Levofloxacin
25
Sulfadiazine
26
Ciprofloxacin
27
Ofloxacin
28
Norfloxacin
29
Artesunate
30
Telmisartan
31
Aspirin
32
Diclofenac Sodium
33
Leveti racetam
34
Carbidopa
35
Ritonavir
36
Lopinavir
37
Acyclovir
38
Carbamazepine
39
Oxcarbazepine
40
Vitamin B6
41
Levodopa
48 projects have been approved under the Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India (also known as the PLI Scheme for Bulk Drugs). The scheme has an approved outlay of Rs.6,940 crore out of which Rs.87.70 crore has been utilized in disbursement of incentive to approved applicants as of March, 2026. Further, production capacity has been created for 28 APIs/KSMs/DIs. Out of these 10 have not achieved commercial production. As of March 2026, cumulative investment of Rs.5,070.45 crore has been achieved against a committed investment of Rs.4,329.95 crore. The State-wise details of approved projects, committed investment, actual investment made, production capacity approved, capacity created, quantity and value of production achieved and incentive disbursement are placed at Annexure-A.
The list of 41 products approved under PLI scheme for Bulk Drugs is placed at Annexure-B., Out of these, production of following 18 APIs has commenced, thereby reducing import dependency - Penicillin G, Clavulanic Acid, Dexamethasone, Prednisolone, Para Amino Phenol, 1,1 Cyclohexane Diacetic Acid (CDA), Dicyandiamide (DCDA), Atorvastatin, Levofloxacin, Sulfadiazine, Ofloxacin, Norfloxacin, Artesunate, Telmisartan, Lopinavir, Carbamazepine, Oxcarbazepine and Diclofenac Sodium.
Annexure-A
State-wise details of approved projects under PLI Scheme for Bulk Drugs
* Projects in state of Haryana and UT of J&K are under commissioning stage.
Annexure-B
Products approved under PLI scheme for Bulk Drugs
This information was given by Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Lok Sabha today.
Disclaimer: Curated by HT Syndication.
